PEGASYS
(Pegasys)ApprovedSmall molecule
PEGASYS is one of 227 small molecule programs targeting Liver Transplant. It is currently in Approved.
7
Indications
41
Total Trials
0
Active Trials
226
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1PEGASYS
Ppharmaand GmbH
Approved
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis24 trials
Show 21 more trials
Essential Thrombocythemia3 trials
Hepatitis B2 trials
10 more indications
Tics1 trial
Liver Transplant1 trial
Adult Subject1 trial
Absorption1 trial
Efficacy1 trial
Tolerance1 trial
Regulatory
FDA Approval Timeline[4]
Oct 16, 2002
PEGASYS
BLA BLA103964
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegasys. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- Ppharmaand GmbH